Trial Profile
A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine H7N9 (Primary) ; Matrix M
- Indications Influenza A virus H7N9 subtype
- Focus Therapeutic Use
- Sponsors Novavax
- 30 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 23 Sep 2014 Positive top-line results published in Novavax media release.
- 06 Aug 2014 According to a Novavax media release, topline data are expected in the third quarter of 2014.